慢性淋巴细胞白血病:2025年流行病学、发病机制、诊断与治疗更新
慢性淋巴细胞白血病(CLL)是最常见的白血病类型,多见于老年患者,临床病程高度异质。诊断依靠血细胞计数、血涂片和循环B淋巴细胞免疫表型分析。Rai和Binet临床分期系统及多种生物学和遗传标记提供预后信息,del(17p)和/或TP53突变预示多数靶向治疗进展时间较短。CLL国际预后指数(CLL-IPI)整合遗传、生物学和临床变量识别不同风险组。仅有活动性或症状性疾病或晚期Binet或Rai分期患者需要治疗。治疗选择包括BCL2抑制剂维奈克拉联合奥妥珠单抗、维奈克拉联合伊布替尼或BTK抑制剂单药治疗。复发时,若无治疗间期超过3年可重复初始治疗,否则应更换方案。靶向药物联合方案提供固定疗程的高效治疗,但治愈率未知,最佳序贯顺序待确定,BTK和BCL2双难治患者需在实验方案中接受新药治疗。
要点
- CLL诊断依靠血细胞计数、血涂片和循环B淋巴细胞免疫表型分析,确认携带CD5抗原及典型B细胞标记的克隆性B细胞群。
- del(17p)和/或TP53突变预示多数靶向治疗进展时间较短。
- 仅有活动性或症状性疾病或晚期Binet或Rai分期患者需要治疗。
核心结论
- CLL是最常见的白血病类型,多见于老年患者,临床病程高度异质。
- 白血病变转化由特定基因组改变启动,干扰克隆性B细胞的增殖和凋亡调控。
- 靶向药物联合方案提供固定疗程的高效治疗,产生深度持久缓解,但治愈率未知,最佳序贯顺序待确定。
- 对BTK和BCL2抑制剂双难治的患者需在实验方案中接受新药治疗。
研究设计与样本
- 综述,总结CLL的流行病学、发病机制、诊断、预后与治疗进展。
主要发现
- 诊断通过血细胞计数、血涂片和循环B淋巴细胞免疫表型分析确定,识别携带CD5抗原及典型B细胞标记的克隆性B细胞群。
- Rai和Binet两种临床分期系统利用体格检查和血细胞计数结果提供预后信息。
- del(17p)和/或TP53基因突变预示多数靶向治疗进展时间较短。
- CLL-IPI整合遗传、生物学和临床变量识别不同风险组,在靶向药物时代仍保持意义,但高危分期患者总体预后已改善。
- 靶向药物联合方案具有成本效益、避免耐药出现并提供无治疗时间,在CLL管理中占据更多地位。
关键数值与推荐
- 仅有活动性或症状性疾病或晚期Binet或Rai分期患者需要治疗。
- 治疗选择包括BCL2抑制剂维奈克拉联合奥妥珠单抗、维奈克拉联合伊布替尼或BTK抑制剂单药治疗。
- 复发时若无治疗间期超过3年可重复初始治疗,若复发更早应更换替代方案。
- 对BTK和BCL2抑制剂双难治的患者需在实验方案中接受新药治疗。
临床怎么用
- CLL诊断依靠血细胞计数、血涂片和循环B淋巴细胞免疫表型分析。
- 使用Rai和Binet临床分期系统及生物学和遗传标记提供预后信息。
- 仅有活动性或症状性疾病或晚期Binet或Rai分期患者才需要治疗。
- 治疗可选择维奈克拉联合奥妥珠单抗、维奈克拉联合伊布替尼或BTK抑制剂单药。
- 复发时根据无治疗间期是否超过3年决定重复初始治疗或更换替代方案。
局限性
- 固定疗程联合方案的治愈率未知。
- 靶向治疗的最佳序贯顺序仍需确定。
- 对BTK和BCL2抑制剂双难治患者的治疗是医学挑战,需在实验方案中接受新药治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia. It typically occurs in older patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and apoptosis in clonal B-cells. DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen as well as typical B-cell markers. PROGNOSIS AND STAGING: Two clinical staging systems, Rai and Binet, provide prognostic information by using the results of physical examination and blood counts. Various biological and genetic markers provide additional prognostic information. Deletions of the short arm of chromosome 17 (del(17p)) and/or mutations of the TP53 gene predict a shorter time to progression with most targeted therapies. The CLL international prognostic index (CLL-IPI) integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. The CLL-IPI retains its significance in the era of targeted agents, but the overall prognosis of CLL patients with high-risk stages has improved. THERAPY: Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist: combinations of the BCL2 inhibitor venetoclax with obinutuzumab, or venetoclax with ibrutinib, or monotherapy with one of the inhibitors of Bruton tyrosine kinase (BTK). At relapse, the initial treatment may be repeated if the treatment-free interval exceeds 3 years. If the leukemia relapses earlier, therapy should be changed using an alternative regimen. FUTURE CHALLENGES: Combinations of targeted agents now provide efficient therapies with a fixed duration that generate deep and durable remissions. These fixed-duration therapies have gained territory in the management of CLL, as they are cost-effective, avoid the emergence of resistance, and offer treatment free time to the patient. The cure rate of these novel combination regimens is unknown. Moreover, the optimal sequencing of targeted therapies remains to be determined. A medical challenge is to treat patients who are double-refractory to both BTK and BCL2 inhibitors. These patients need to be treated within experimental protocols using novel drugs.
引用
- Hallek M. Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025. PMID: 39871707. doi:10.1002/ajh.27546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。